The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions

NCT ID: NCT00670436

Last Updated: 2014-06-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to assess the safety and efficacy of a Paclitaxel-eluting PTCA-balloon in combination with bare-metal stenting for treatment of chronic total occlusions in native coronary arteries with reference diameters between 2.5 mm and 4.0 mm.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Chronic Total Occlusion Native Coronary Artery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A 1

paclitaxel eluting PTCA balloon (SeQuent please) after bare-metal stenting of a chronic total occlusion in a native coronary artery

Group Type ACTIVE_COMPARATOR

paclitaxel eluting PTCA balloon catheter (SeQuent Please)

Intervention Type DEVICE

paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery

A2

historical population of patients with a chronic total occlusion in a native coronary artery treated with the paclitaxel eluting Taxus stent (Boston Scientific)

Group Type ACTIVE_COMPARATOR

paclitaxel eluting Taxus stent (Boston Scientific)

Intervention Type DEVICE

paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

paclitaxel eluting PTCA balloon catheter (SeQuent Please)

paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery

Intervention Type DEVICE

paclitaxel eluting Taxus stent (Boston Scientific)

paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SeQuent Please paclitaxel eluting balloon

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* chronic total occlusion
* Thrombolysis in Myocardial Infarction (TIMI) flow 0 or 1
* occlusion in native coronary artery
* indication for percutaneous coronary intervention based on symptoms, prognosis or evidence of ischemia
* reference diameter 2.5 mm to 4.0 mm

Exclusion Criteria

* saphenous vein graft
* bifurcation lesion with need to stent main and side branch
* left main occlusion
* de-novo stenosis (no occlusion)
* restenosis
* in-stent restenosis
* contraindication for dual antiplatelet therapy with acetylsalicylic acid and clopidogrel for 6 months
* coronary aneurysm at target lesion
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

B. Braun Melsungen AG

INDUSTRY

Sponsor Role collaborator

University of Ulm

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jochen Wohrle

Prof. Dr. Jochen Wöhrle

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jochen Wöhrle, MD; FESC

Role: PRINCIPAL_INVESTIGATOR

University of Ulm, Ulm, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Klinikum Darmstadt

Darmstadt, , Germany

Site Status

University of Ulm

Ulm, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Wohrle J, Werner GS. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. Catheter Cardiovasc Interv. 2013 Apr;81(5):793-9. doi: 10.1002/ccd.24409. Epub 2012 Nov 8.

Reference Type BACKGROUND
PMID: 22511572 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PEPCAD-CTO V 2.3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.